Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Resmed (RSMDF) Equity Average (2016 - 2025)

Historic Equity Average for Resmed (RSMDF) over the last 16 years, with Q4 2025 value amounting to $6.2 billion.

  • Resmed's Equity Average rose 1908.6% to $6.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $6.2 billion, marking a year-over-year increase of 1908.6%. This contributed to the annual value of $5.4 billion for FY2025, which is 2043.55% up from last year.
  • Resmed's Equity Average amounted to $6.2 billion in Q4 2025, which was up 1908.6% from $6.0 billion recorded in Q3 2025.
  • Resmed's Equity Average's 5-year high stood at $6.2 billion during Q4 2025, with a 5-year trough of $2.8 billion in Q1 2021.
  • In the last 5 years, Resmed's Equity Average had a median value of $4.1 billion in 2023 and averaged $4.2 billion.
  • The largest annual percentage gain for Resmed's Equity Average in the last 5 years was 2347.26% (2021), contrasted with its biggest fall of 1132.86% (2021).
  • Quarter analysis of 5 years shows Resmed's Equity Average stood at $3.1 billion in 2021, then grew by 16.19% to $3.6 billion in 2022, then rose by 21.77% to $4.4 billion in 2023, then increased by 19.65% to $5.2 billion in 2024, then increased by 19.09% to $6.2 billion in 2025.
  • Its last three reported values are $6.2 billion in Q4 2025, $6.0 billion for Q3 2025, and $5.8 billion during Q2 2025.